Rilutek Use, Time to ALS Diagnosis Vary Across Canadian Provinces, Study Shows

The amount of time it takes to diagnose amyotrophic lateral sclerosis (ALS) and the use of Rilutek (riluzole) to treat it vary significantly across Canada, according to a new nationwide analysis of a patient registry. These findings highlight the need for future studies to identify the factors that contribute…

About four years ago, ALS impeded my speaking ability. Like more than 80 percent of all ALS patients, I now have dysarthria, or what I refer to as my “ALS voice.” It’s a slurred, slow speech pattern with a nasal tone and imprecise pronunciation of consonants. For…

The U.S. Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) of Biohaven Pharmaceuticals’ BHV-0223, a sublingual (dissolved under the tongue) form of riluzole, as a treatment for amyotrophic lateral sclerosis (ALS). Biohaven has begun enrollment of ALS patients for its Phase 2/3…

Before ALS, whenever I thought about the future, I assumed my life would continue in a state of health and happiness, filled with lots of interesting activities. But in 2010, when I learned I had ALS, thinking about my future became very dismal and frightening. My mind…

Health conditions that may lead to a faster metabolism, or higher metabolic rate, may contribute to the development of amyotrophic lateral sclerosis (ALS), a large-scale, population-based study suggests. The study, “Finding diseases associated with amyotrophic lateral sclerosis: a total population-based case–control study,” was published in the…

Mutations that affect a particular molecular pathway essential to protein production further support reports of a link between amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). The study detailing this finding, “The neurodegenerative diseases ALS and SMA are linked at the molecular level via the ASC-1 complex,”…